Publication date: Dec 31, 2024
Solid organ transplant recipients (SOTRs) are considered a high-risk group for coronavirus disease 2019 (COVID-19). The adaptive immune responses generated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination include humoral and cellular immune responses. Most studies on the SARS-CoV-2 vaccine have focused primarily on humoral immunity, but cellular immunity is vital for effectively controlling progression to severe COVID-19. In SOTRs, the vaccine-induced adaptive immune response is significantly attenuated compared to the response in healthy individuals. Nevertheless, vaccinated SOTRs exhibit a reduced rate and severity of SARS-CoV-2 infection. This review aims to provide a concise overview of the current understanding of SARS-CoV-2 vaccine-induced immune responses in SOTRs.
| Concepts | Keywords |
|---|---|
| Covid | Cellular immune responses |
| Healthy | Humoral immune responses |
| Organ | SARS-CoV-2 vaccine |
| Transplant | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | coronavirus disease 2019 |
| disease | IDO | adaptive immune response |
| pathway | REACTOME | SARS-CoV-2 Infection |